

Xbrane Biopharma presents Nomination Committee

In accordance with the principles of the Nomination Committee of Xbrane Biopharma AB ("Company" or "Xbrane"), adopted at the Annual General Meeting ("AGM") on May 4th, 2023, The nomination committee, which shall be appointed for the time until a new nomination committee has been appointed, shall consist of three members, whom shall be nominated by the Company's three largest shareholders with respect to voting power as per 30 September 2023. The chairman of the board shall be a co-opted member when necessary. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights.

Based on the above, the Nomination Committee for the AGM in 2024 has been set up to consist of the following, which together represent approximately 25 percent of the number of shares and votes in the Company as of September 30, 2023:

- Ashkan Pouya, appointed by Serendipity Group AB, the Company's largest shareholder,
- Bengt Göran Westman, the Company's second largest shareholder
- Oscar Bergman appointed by Swedbank Robur Fonder, the Company's third largest shareholder
- Anders Tullgren, Chairman of the Company co-opted member,

The task of the Nomination Committee is prior to AGM prepare and submit proposals regarding the Chairman of the AGM, candidates for the post of chairman and other directors of the board, fees, and other remuneration for board work to each director, fees to members of committees within the board, election and remuneration of the Company auditor and principles for the nomination committee. The Nomination Committee's proposal will be presented in the notice to the AGM 2024 and on the Company's website, www.xbrane.com.

Shareholders may submit proposals to the Nomination Committee for the AGM on May 2nd, 2024, until January 22, 2024. The proposals can be sent to the following address: Xbrane Biopharma AB Nomination Committee, c/o Xbrane Biopharma AB, Retzius väg 8, 171 65 Solna, Sweden, or via email: valberedning@xbrane.com.

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Attachments

[Xbrane Biopharma presents Nomination Committee](#)